Mark Romereim, MD
Psychiatry · Hays, KSNPI 1578621140
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,300 of the $41,454 with a category attached, or 77.9%. 16 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 57.6% of the total. Reporting peaked in 2024 at $27,125 and has fallen 51.0% since, to $13,300 in 2025. Among psychiatry clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $398.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$24K
- Axsome Therapeutics, Inc.$13K
- Neuronetics, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$750
- Johnson & Johnson$460
- AbbVie$238
- plus $542 from 10 others
What the payments were for
- Consulting fees$6081%
- Speaking & faculty fees$32,30078%
- Travel & lodging$4,60411%
- Food & beverage$3,7229%
- Education$2201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 41 | $23,888 |
| Axsome Therapeutics, Inc. | 17 | $13,112 |
| Neuronetics, Inc. | 10 | $2,464 |
| Otsuka America Pharmaceutical, Inc. | 3 | $750 |
| Johnson & Johnson | 7 | $460 |
| AbbVie(2 entities) | 9 | $238 |
| E.r. Squibb & Sons, L.L.C. | 6 | $177 |
| Teva Pharmaceuticals USA, Inc. | 2 | $127 |
| Neurocrine Biosciences, Inc. | 1 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $66 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Brainsway USA Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,454 in reported general payments places this provider in the 95th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 251 | $304,660 |
| Invega SustennaPaliperidone Palmitate | 69 | $235,056 |
| IngrezzaValbenazine Tosylate | 11 | $94,023 |
| TrintellixVortioxetine Hydrobromide | 180 | $90,936 |
| VraylarCariprazine Hcl | 57 | $76,711 |
| Abilify MaintenaAripiprazole | 16 | $45,647 |
| VivitrolNaltrexone Microspheres | 14 | $25,303 |
| QuviviqDaridorexant Hcl | 39 | $18,363 |
| RexultiBrexpiprazole | 13 | $18,001 |
| MounjaroTirzepatide | 12 | $14,295 |
| QelbreeViloxazine Hcl | 14 | $9,678 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 189 | $9,127 |
| Aripiprazole | 133 | $8,151 |
| Paliperidone ErPaliperidone | 50 | $8,030 |
| Varenicline Tartrate | 26 | $7,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $460 | $539,715320 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $16 | $96,454194 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $72 | $94,02311 claims |
| AbbVieVraylar, Fetzima | $238 | $82,16168 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $750 | $63,64829 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $23,888 | $9,67814 claims |
| Eisai Inc.Dayvigo | $14 | $4,13813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Hays
- David WichmanManhattan$613K
- Kevin MaysLeawood$548K
- Sheldon PreskornWichita$498K
- James OwensSalina$433K
- Sasha HamdaniOverland Park$104K
- Christine GlennKansas City$58K
- Heidi OgdenWichita$55K
- Patrick StangGreat Bend$28K
- Ralph BharatiWichita$26K
- Sonni ElliottLeawood$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.